

# Elisa Oricchio

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3204551/publications.pdf>

Version: 2024-02-01

20  
papers

1,453  
citations

686830

13  
h-index

794141

19  
g-index

21  
all docs

21  
docs citations

21  
times ranked

3005  
citing authors

#	ARTICLE	IF	CITATIONS
1	Genome-wide RNA-mediated interference screen identifies miR-19 targets in Notch-induced T-cell acute lymphoblastic leukaemia. <i>Nature Cell Biology</i> , 2010, 12, 372-379.	4.6	316
2	Loss of the HVEM Tumor Suppressor in Lymphoma and Restoration by Modified CAR-T Cells. <i>Cell</i> , 2016, 167, 405-418.e13.	13.5	204
3	Comparison of computational methods for the identification of topologically associating domains. <i>Genome Biology</i> , 2018, 19, 217.	3.8	160
4	The Eph-Receptor A7 Is a Soluble Tumor Suppressor for Follicular Lymphoma. <i>Cell</i> , 2011, 147, 554-564.	13.5	151
5	De novo protein design enables the precise induction of RSV-neutralizing antibodies. <i>Science</i> , 2020, 368, .	6.0	137
6	Targeting cap-dependent translation blocks converging survival signals by AKT and PIM kinases in lymphoma. <i>Journal of Experimental Medicine</i> , 2011, 208, 1799-1807.	4.2	103
7	EZH2 oncogenic mutations drive epigenetic, transcriptional, and structural changes within chromatin domains. <i>Nature Genetics</i> , 2019, 51, 517-528.	9.4	102
8	Cathepsin S Regulates Antigen Processing and T Cell Activity in Non-Hodgkin Lymphoma. <i>Cancer Cell</i> , 2020, 37, 674-689.e12.	7.7	55
9	Genetic and epigenetic inactivation of <i>SESTRIN1</i> controls mTORC1 and response to EZH2 inhibition in follicular lymphoma. <i>Science Translational Medicine</i> , 2017, 9, .	5.8	52
10	Systematic inference and comparison of multi-scale chromatin sub-compartments connects spatial organization to cell phenotypes. <i>Nature Communications</i> , 2021, 12, 2439.	5.8	50
11	Histone acetylation dynamics modulates chromatin conformation and allele-specific interactions at oncogenic loci. <i>Nature Genetics</i> , 2021, 53, 650-662.	9.4	34
12	Frequent disruption of the RB pathway in indolent follicular lymphoma suggests a new combination therapy. <i>Journal of Experimental Medicine</i> , 2014, 211, 1379-1391.	4.2	32
13	Pan-SRC kinase inhibition blocks B-cell receptor oncogenic signaling in non-Hodgkin lymphoma. <i>Blood</i> , 2018, 131, 2345-2356.	0.6	22
14	Mining the cancer genome uncovers therapeutic activity of EphA7 against lymphoma. <i>Cell Cycle</i> , 2012, 11, 1076-1080.	1.3	10
15	A Cell Engineering Strategy to Enhance the Safety of Stem Cell Therapies. <i>Cell Reports</i> , 2014, 8, 1677-1685.	2.9	9
16	Mouse models of cancer as biological filters for complex genomic data. <i>DMM Disease Models and Mechanisms</i> , 2010, 3, 701-704.	1.2	6
17	Functional genomics lead to new therapies in follicular lymphoma. <i>Annals of the New York Academy of Sciences</i> , 2013, 1293, 18-24.	1.8	4
18	Epigenetic balance in DLBCL. <i>Blood</i> , 2021, 138, 355-356.	0.6	2

#	ARTICLE	IF	CITATIONS
19	Sestrin1, a tumor suppressor that can be rescued. <i>Molecular and Cellular Oncology</i> , 2017, 4, e1365107.	0.3	1
20	Genomic Studies Indicate A Novel Combination Therapy For Follicular Lymphoma. <i>Molecular and Cellular Oncology</i> , 2014, 8, 00-00.	0.3	0